Eukaryotic Cell Carrier for AChR Autoantibody Detection
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current immunofluorescence assays for detecting autoantibodies to the acetylcholine receptor in myasthenia gravis lack sufficient sensitivity and specificity, and the use of radioactive isotopes in RIA assays poses safety concerns, necessitating the development of a non-radioactive, more sensitive method for diagnostic reliability.
Innovation Solution
A diagnostically useful carrier comprising eukaryotic cells overexpressing adult and fetal ACh receptors, pre-fixed for immunofluorescence, is used in conjunction with a fluorescent ligand to enhance the sensitivity of the assay, allowing for the detection of autoantibodies in patient samples, potentially replacing RIA assays by standardizing the pre-fixing process and improving diagnostic reliability.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Measurement precision
If RIA assay is used for detecting autoantibodies to AChR, then sensitivity is improved, but safety deteriorates due to use of radioactive isotopes
Solution Approach 1:
The patent replaces the radioactive detection system (RIA) with a fluorescent detection system (immunofluorescence assay). Instead of using radioactive isotopes to label AChR and detect autoantibodies, the invention uses fluorescently labeled secondary antibodies that bind to autoantibodies bound to fixed cells expressing AChR. This substitution eliminates radioactive hazards while maintaining diagnostic sensitivity through optical detection methods.
2Object-affected harmful factors
If conventional immunofluorescence assay is used for detecting autoantibodies, then safety is improved by eliminating radioactive isotopes, but sensitivity deteriorates compared to RIA
Solution Approach 1:
The patent applies preliminary action by pre-fixing the cells expressing AChR before the diagnostic assay is performed. This pre-fixing step stabilizes the AChR on the cell surface, ensures consistent antigen presentation, and prevents cell degradation during storage and handling. By preparing the cellular substrate in advance with optimized AChR expression and fixation conditions, the assay achieves sensitivity comparable to or exceeding RIA while maintaining the safety advantages of non-radioactive methods.
3Reliability
If immunofluorescence assay is standardized with pre-fixed cells, then reliability is improved, but device complexity increases due to additional pre-processing steps
Solution Approach 1:
The patent resolves this contradiction by performing the complex cell fixation and AChR expression optimization steps in advance, before the actual diagnostic assay. The cells are cultured to express AChR, fixed under optimized conditions, and stored as ready-to-use substrates. This preliminary preparation transfers complexity from the point-of-care diagnostic step to the manufacturing phase, making the clinical assay simple and reliable while maintaining high diagnostic accuracy.
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
The method significantly increases the sensitivity of immunofluorescence assays for detecting autoantibodies to ACh receptors, enabling earlier and more accurate diagnosis of myasthenia gravis, while eliminating the need for radioactive isotopes, thereby improving diagnostic reliability and safety.
Implementation Method 1
contacting said carrier with a patient sample and a fluorescent ligand under conditions allowing formation of a complex comprising an autoantibody from the group comprising an autoantibody to ACh receptor and a fluorescent ligand binding to said autoantibody
Data Source
Figure 1
Figure 2A~2D
AI summary
The present invention relates to a diagnostically useful carrier comprising a eukaryotic cell overexpressing an adult ACh receptor or a variant thereof and a eukaryotic cell overexpressing a fetal ACh receptor or a variant thereof, wherein the cell is fixed for immunofluorescence and a method comprising the step of contacting said carrier with a patient sample and a use of a use of the combination of a eukaryotic cell overexpressing an adult ACh receptor or a variant thereof and a eukaryotic cell overexpressing a fetal ACh receptor or a variant thereof for increasing the sensitivity of an assay, preferably immunofluorescence assay, for the detection of an autoantibody to ACh receptor.